The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert on the circulation of substandard batches of Annmox (Amoxicillin suspension 125mg/5ml) and Jawamox (Amoxicillin suspension 125mg/5ml) manufactured by Jawa International Ltd.
According to the agency, laboratory analysis confirmed that the affected batches, Annmox Batch 360M and Jawamox Batches 4231M and 4290M, failed quality tests due to low Active Pharmaceutical Ingredient (API) content.
“NAFDAC is notifying the public of the mop-up of batches of confirmed substandard Annmox (Batch 360M) and Jawamox (Batch 4231M & 4290M) suspensions,” the agency stated in a post shared on Friday.
Read Also: NAFDAC warns Nigerians over circulation of fake Cialis tablets
Consequently, the apex food and product control agency has directed the company to recall the defective batches from the market and initiated a nationwide mop-up exercise.
The agency warned that medicines with low levels of active ingredients pose significant health risks, including ineffective treatment, the development of antimicrobial resistance, and potential complications resulting from inadequate therapy.
It further noted that the marketing of substandard medicines undermines public confidence in pharmaceutical products and endangers public health.
NAFDAC urged healthcare professionals and consumers to report any suspected substandard or falsified medicines to its nearest office, via its toll-free number 08001623322, or by email at [email protected].
